Compare WAB & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAB | ONC |
|---|---|---|
| Founded | 1869 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.8B | 34.8B |
| IPO Year | 1995 | N/A |
| Metric | WAB | ONC |
|---|---|---|
| Price | $230.56 | $341.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $245.44 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 656.9K | 295.1K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | ★ 14.53 | N/A |
| EPS | ★ 6.87 | 0.58 |
| Revenue | ★ $10,785,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $7.61 | $895.40 |
| Revenue Next Year | $8.16 | $22.04 |
| P/E Ratio | ★ $33.85 | $598.59 |
| Revenue Growth | 4.41 | ★ 50.43 |
| 52 Week Low | $151.81 | $196.45 |
| 52 Week High | $236.00 | $385.22 |
| Indicator | WAB | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 58.97 | 55.02 |
| Support Level | $227.08 | $334.36 |
| Resistance Level | $233.67 | $353.00 |
| Average True Range (ATR) | 4.10 | 9.92 |
| MACD | -0.23 | 0.79 |
| Stochastic Oscillator | 58.44 | 59.61 |
Westinghouse Air Brake Technologies Corp provides value-added, technology-based products and services for the freight rail and passenger transit industries and the mining, marine, and industrial markets. It provides its products and services through two main business segments: Freight and Transit. The company generates maximum revenue from the Freight segment, which manufactures new and modernized locomotives, provides aftermarket parts and services to existing locomotives, provides components to new and existing freight cars; builds new commuter locomotives; supplies rail control and infrastructure products, including electronics, positive train control equipment, signal design, and engineering services. Geographically, it generates a majority of its revenue from the United States.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.